{"id":"NCT00404651","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants","officialTitle":"Lot to Lot Consistency Study of DTaP-IPV-Hep B-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Mexican Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-04","completion":"2008-07","firstPosted":"2006-11-29","resultsPosted":"2014-05-09","lastUpdate":"2014-05-09"},"enrollment":1189,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Poliomyelitis"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-IPV-HB-PRP~T vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-IPV-HB-PRP~T vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-IPV-HB-PRP~T vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-HBV-IPV vaccine","otherNames":["INFANRIX®HEXA"]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"},{"label":"Group 4","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this trial is to clinically confirm that the manufacturing process of the final bulk products of the investigational DTaP-IPV-HB-PRP\\~T vaccine is consistent.\n\nThe primary objective is to demonstrate the equivalence of three batches of DTaP-IPV-HB-PRP\\~T vaccine, in terms of seroprotection and seroconversion rates for the vaccine antigens after the three-dose primary series.\n\nThe secondary objectives are:\n\n* To describe in each group, the immunogenicity parameters for all antigens one month after the third dose of the primary series\n* To assess the overall safety in each group one month after the third dose of the primary series.","primaryOutcome":{"measure":"Equivalence of Seroprotection Against Vaccine Antigens in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™ Vaccine","timeFrame":"Day 150 (one month post-dose 3)","effectByArm":[{"arm":"DTaP-IPV-HB-PRP~T Batch 1","deltaMin":226,"sd":null},{"arm":"DTaP-IPV-HB-PRP~T Batch 2","deltaMin":231,"sd":null},{"arm":"DTaP-IPV-HB-PRP~T Batch 3","deltaMin":221,"sd":null},{"arm":"Infanrix Hexa™","deltaMin":119,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":6,"countries":["Mexico"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":337},"commonTop":["Injection Site Pain","Irritability","Crying","Somnolence","Injection Site Erythema"]}}